indirubin has been researched along with transforming growth factor beta in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alborzinia, H; Cheng, X; Eisenbrand, G; Kitanovic, I; Merz, KH; Mrowka, R; Scholl, C; Steinbeisser, H; Wölfl, S | 1 |
| Du, Z; Li, S; Li, Y; Peng, H; Pu, W; Wei, F; Zhang, T; Zhang, Y; Zhou, Q; Zhou, X | 1 |
2 other study(ies) available for indirubin and transforming growth factor beta
| Article | Year |
|---|---|
Indirubin derivatives modulate TGFβ/BMP signaling at different levels and trigger ubiquitin-mediated depletion of nonactivated R-Smads.
Topics: Animals; Bone Morphogenetic Proteins; Embryo, Nonmammalian; Fibroblasts; Gene Expression Regulation, Developmental; HeLa Cells; Humans; Indoles; Jurkat Cells; MAP Kinase Signaling System; Phosphorylation; Protein Kinase Inhibitors; RNA, Small Interfering; Signal Transduction; Smad Proteins, Receptor-Regulated; Transforming Growth Factor beta; Ubiquitin; Ubiquitin Thiolesterase; Xenopus | 2012 |
Indirubin regulates T cell differentiation by promoting αVβ8 expression in bone marrow-derived dendritic cells to alleviate inflammatory bowel disease.
Topics: Animals; Bone Marrow; Cell Differentiation; Cells, Cultured; Cytokines; Dendritic Cells; Inflammatory Bowel Diseases; Mice; Mice, Inbred C57BL; RNA, Small Interfering; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2023 |